Sarepta Therapeutics (SRPT) moved back into focus after management raised 2026 net product revenue guidance to a range of US$1.25b to US$1.3b, increasing the low end by US$50m.
The raised guidance comes at a tougher time for Sarepta Therapeutics shareholders. The share price is down 24.59% year to date, and the 3-year total shareholder return has fallen 80.67%. This suggests recent optimism has not yet reversed the longer-term slide.
Scan beyond Sarepta Therapeutics and see how other rare disease and biotech players are setting up with our curated list of 19 high quality undiscovered gems.
Sarepta Therapeutics now points to higher future product sales, yet the share price has retreated sharply. Is this a solid rare disease platform temporarily marked down, or is the market already close to fair on the new outlook?
The analyst consensus Narrative on Simply Wall St places Sarepta Therapeutics fair value at $21.73 per share, above the last close of $16.07. This frames the recent revenue guidance lift against a still discounted share price and a pipeline-heavy story.
Sarepta Therapeutics is using a cash flow positive Duchenne muscular dystrophy portfolio, with Q2 2026 product gross margins of 75% and non GAAP operating income of US$86 million, to self fund pipeline work and potentially support future earnings and cash generation without relying on new equity.
The siRNA program in FSHD, where SRP 1001 single ascending dose data showed over 90% correction on DUX4 regulated gene panels and a favorable safety profile, points to a possible new neuromuscular revenue contributor that could sit alongside the existing PMO franchise.
See why 43 investors see Sarepta Therapeutics as 26% undervalued.
Result: Fair Value of $21.73 (UNDERVALUED)
Still, the Sarepta Therapeutics narrative relies on cleaner ELEVIDYS safety data and timely siRNA progress, both of which could disappoint and weaken the cash flow story.
Find out about the key risks to this Sarepta Therapeutics narrative.
Mixed signals can be confusing, especially when Sarepta Therapeutics has both risks and potential upsides on the table. Move quickly and test the thesis against your own research using the full breakdown of 3 key rewards and 1 important warning sign.
Do not stop your research with Sarepta Therapeutics alone. A few targeted screens can open up very different ways to put your next dollar to work.
Expand your opportunity set beyond the usual tickers by scanning our 34 high quality undervalued stocks, which combines strong fundamentals with prices below intrinsic estimates.
Prioritise resilience first by using the 29 resilient stocks with low risk scores, which focuses on businesses with sturdier financial and risk profiles.
Target financial strength and staying power by filtering for companies in the list of solid balance sheet and fundamentals (24 results) before you commit fresh capital.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com